MIM
VIGL

MetLife Investment Management’s Vigil Neuroscience VIGL Stock Holding History

MetLife Investment Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,105
Closed -$85.6K – 2984
2023
Q2 		$85.6K Buy
+9,105
New +$86.1K ﹤0.01% 2774

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

MetLife Investment Management's VIGL Position: Q3 2023 in Review

MetLife Investment Management sold out of Vigil Neuroscience (VIGL) in Q3 2023, closing a stake of 9,105 shares — an estimated $85.6K sold.

MetLife Investment Management first reported a position in VIGL in Q2 2023 and held it in 1 quarter. The position peaked at $85.6K in Q2 2023. 45 funds tracked by Wall St. Rank hold VIGL as of Q3 2023.

  • MetLife Investment Management reported no remaining Vigil Neuroscience position as of Q3 2023 after selling out during the quarter.
  • MetLife Investment Management sold 9,105 Vigil Neuroscience shares in Q3 2023, an estimated $85.6K.
  • MetLife Investment Management first reported a position in Vigil Neuroscience in Q2 2023 and held it in 1 quarter.
  • MetLife Investment Management's Vigil Neuroscience position peaked at $85.6K in Q2 2023.
  • 45 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.